Last updated: March 14, 2026
What is NDC 31722-0443?
NDC 31722-0443 corresponds to Ubrogepant, marketed as Ubrelvy. Ubrogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist indicated for acute treatment of migraine with or without aura in adults. Approved by the FDA in 2019, it is positioned as an alternative to triptans, targeting patients with contraindications or insufficient response to existing therapies.
Market Landscape Overview
Market Size
The migraine therapeutics market is valued at approximately USD 4-5 billion in 2022, with Ubrogepant capturing an estimated 10-15% share, depending on regional penetration. Growth driven by increasing migraine prevalence, unmet need for acute treatments, and expanding insurance coverage.
Epidemiology
- US prevalence: circa 39 million adults[1].
- Estimated annual migraine attack episodes: 200 million nationwide.
- Market penetration is 2-3% as of 2022, projected to rise to 5-8% over five years as prescriber familiarity increases.
Competition
Main competitors include:
- Triptans (e.g., Sumatriptan, Rizatriptan)
- Ditans (e.g., Lasmiditan)
- Other CGRP antagonists (e.g., rimegepant, atogepant)
Ubrogepant's differentiation lies in its non-vasoconstrictive profile, suitable for patients with cardiovascular risks.
Price Analysis
Current Pricing
- Average wholesale price (AWP): USD 31–35 per tablet[2].
- Average out-of-pocket cost (with insurance): USD 10–25 per dose, depending on co-pay and insurance plan.
Pricing Trends
- The initial launch price in 2019 was approximately USD 30 per tablet.
- In 2022, price reductions of 5–10% observed as generic competition edges closer and as rebate negotiations improve.
- Manufacturer promotional discounts and copay assistance programs influence affordability.
Revenue Projections
| Year |
Estimated Market Share |
Expected Prescriptions |
Revenue Estimate (USD millions) |
| 2023 |
4% |
1.2 million |
36 |
| 2024 |
6% |
1.8 million |
54 |
| 2025 |
8% |
2.4 million |
72 |
| 2026 |
10% |
3 million |
90 |
Assumptions:
- Steady growth in prescriptions due to increased clinician familiarity.
- Pricing stabilizes around USD 30 per tablet with no significant discounts or access barriers.
Pricing Strategy and Market Drivers
- Payer dynamics: insurers favor drug pricing that balances cost and efficacy.
- Patient preferences: demand for quick onset, fewer side effects.
- Regulatory developments: potential expansion of indications could increase utilization.
- Reimbursement policies: shifting toward value-based models may influence pricing adjustments.
Key Market Risks
- Generic entry: scheduled for 2025-2026, likely undercuts branded pricing.
- Market entry of alternative therapies: new CGRP antagonists or non-pharmacologic interventions.
- Pricing pressures: health policy reforms targeting drug spending.
Summary
Ubrogepant (NDC 31722-0443) faces a competitive environment with a current retail price of USD 30–35 per tablet, complemented by insurance coverage that lowers patient costs. Revenue growth hinges on increasing prescriber adoption, expanding indications, and navigating upcoming patent challenges with generics. Price erosion anticipated post-2025 with generic availability.
Key Takeaways
- The US migraine drugs market is expected to grow at a compound annual growth rate (CAGR) of approximately 5% through 2027.
- Ubrogepant is positioned as a niche alternative with favorable safety in cardiovascular patients.
- Pricing remains relatively stable; significant drops are likely after patent expiration.
- Market share growth depends on prescription pipeline expansion and reimbursement strategies.
- The looming patent cliff in 2025-2026 will influence pricing and market share dynamics.
FAQs
Q1: What factors influence Ubrogepant's pricing?
Pricing depends on manufacturer strategies, insurance negotiations, rebate programs, and competitive dynamics, especially as patents expire.
Q2: How does Ubrogepant compare price-wise to triptan therapies?
It costs roughly the same or slightly higher per tablet but is positioned for specific patient populations where triptans are contraindicated.
Q3: When will generics likely enter the market?
Patent expiration is expected around 2025-2026, which could lead to significant price reductions.
Q4: What are the key drivers for expanding Ubrogepant's market?
Increasing awareness among physicians, expanding indications, and improving insurance coverage.
Q5: How might regulatory changes affect Ubrogepant's market?
Potential approvals for preventive use or new formulations could increase total addressable market and influence pricing strategies.
References
[1] Headache Classification Committee of the International Headache Society (2018). The International Classification of Headache Disorders, 3rd edition (ICHD-3). Cephalalgia, 38(1), 1-211.
[2] GoodRx. (2023). Ubrelvy (Ubrogepant) prices and discounts. Retrieved from https://www.goodrx.com
